An in silico drug repurposing approach to identify HDAC1 inhibitors against glioblastoma

References

• Akmal, M., Hasnain, N., Rehan, A., Iqbal, U., Hashmi, S., Fatima, K., Farooq, M. Z., Khosa, F., Siddiqi, J., & Khan, M. K. (2020). Glioblastome multiforme: A bibliometric analysis. World Neurosurgery, 136, 270–282. https://doi.org/10.1016/j.wneu.2020.01.027
   PubMed Web of Science ®Google Scholar
• Albrecht, M., Mittler, A., Wilhelm, B., Lundwall, Å., Lilja, H., Aumüller, G., & Bjartell, A. (2003). Expression and immunolocalisation of neutral endopeptidase in prostate cancer. European Urology, 44(4), 415–422. https://doi.org/10.1016/S0302-2838(03)00322-1
   PubMed Web of Science ®Google Scholar
• Balaji E, V., Satarker, S., Kumar, B. H., Pandey, S., Birangal, S. R., Nayak, U. Y., & Pai, K. S. R. (2023). In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma. Journal of Biomolecular Structure & Dynamics, 42(7), 3764–3789. https://doi.org/10.1080/07391102.2023.2215884
   PubMed Web of Science ®Google Scholar
• Belyaev, N. D., Kellett, K. A. B., Beckett, C., Makova, N. Z., Revett, T. J., Nalivaeva, N. N., Hooper, N. M., & Turner, A. J. (2010). The transcriptionally active amyloid precursor protein (APP) intracellular domain is preferentially produced from the 695 isoform of APP in a β-secretase-dependent pathway*. The Journal of Biological Chemistry, 285(53), 41443–41454. https://doi.org/10.1074/jbc.M110.141390
   PubMed Web of Science ®Google Scholar
• Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021). Recent developments of HDAC inhibitors: Emerging indications and novel molecules. British Journal of Clinical Pharmacology, 87(12), 4577–4597. https://doi.org/10.1111/bcp.14889
   PubMed Web of Science ®Google Scholar
• Carlsson, S. K., Brothers, S. P., & Wahlestedt, C. (2014). Emerging treatment strategies for glioblastoma multiforme. EMBO Molecular Medicine, 6(11), 1359–1370. https://doi.org/10.15252/emmm.201302627
   PubMed Web of Science ®Google Scholar
• Chatterjee, A., Cutler, S. J., Doerksen, R. J., Khan, I. A., & Williamson, J. S. (2014). Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening. Bioorganic & Medicinal Chemistry, 22(22), 6409–6421. https://doi.org/10.1016/j.bmc.2014.09.043
   PubMed Web of Science ®Google Scholar
• Choubey, S. K., & Jeyaraman, J. (2016). A mechanistic approach to explore novel HDAC1 inhibitor using pharmacophore modeling, 3D- QSAR analysis, molecular docking, density functional and molecular dynamics simulation study. Journal of Molecular Graphics & Modelling, 70, 54–69. https://doi.org/10.1016/j.jmgm.2016.09.008
   PubMed Web of Science ®Google Scholar
• Daina, A., Michielin, O., & Zoete, V. (2017). SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports, 7(1), 42717. https://doi.org/10.1038/srep42717
   PubMed Web of Science ®Google Scholar
• de Ruijter, A. J. M., van Gennip, A. H., Caron, H. N., Kemp, S., & van Kuilenburg, A. B. P. (2003). Histone deacetylases (HDACs): Characterization of the classical HDAC family. The Biochemical Journal, 370(Pt 3), 737–749. https://doi.org/10.1042/BJ20021321
   PubMed Web of Science ®Google Scholar
• Ganju, R. K., Sunday, M., Tsarwhas, D. G., Card, A., & Shipp, M. A. (1994). CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. The Journal of Clinical Investigation, 94(5), 1784–1791. https://doi.org/10.1172/JCI117526
   PubMed Web of Science ®Google Scholar
• Grunicke, H., Zwierzina, H., Loidl, A., Helliger, W., & Puschendorf, B. (1984). Alkylating antitumour agents decrease histone acetylation in Ehrlich-Ascites tumour cells. In Cancer Chemotherapy and Selective Drug Development. Springer. pp. 413–417. https://doi.org/10.1007/978-1-4613-3837-6_62
   Google Scholar
• Hiraoka, N., Kikuchi, J., Koyama, D., Wada, T., Mori, S., Nakamura, Y., & Furukawa, Y. (2013). Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma. Blood Cancer Journal, 3(12), e169. https://doi.org/10.1038/bcj.2013.66
   PubMedGoogle Scholar
• Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020). Thirty years of HDAC inhibitors: 2020 insight and hindsight. Journal of Medicinal Chemistry, 63(21), 12460–12484. https://doi.org/10.1021/acs.jmedchem.0c00830
   PubMed Web of Science ®Google Scholar
• Holderbach, S., Adam, L., Jayaram, B., Wade, R. C., & Mukherjee, G. (2020). RASPD+: Fast protein-ligand binding free energy prediction using simplified physicochemical features. Frontiers in Molecular Biosciences, 7, 601065. https://doi.org/10.3389/fmolb.2020.601065
   PubMed Web of Science ®Google Scholar
• Hong, Y., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012). The impact of amyloid precursor protein signalling and histone deacetylase inhibition on neprilysin expression in human prostate cells. International Journal of Cancer, 130(4), 775–786. https://doi.org/10.1002/ijc.26028
   PubMed Web of Science ®Google Scholar
• Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., & Popat, A. (2021). Frontiers in the treatment of glioblastoma: Past, present and emerging. Advanced Drug Delivery Reviews, 171, 108–138. https://doi.org/10.1016/j.addr.2021.01.012
   PubMed Web of Science ®Google Scholar
• Kim, H. K., & Yang, K. I. (2022). Melatonin and melatonergic drugs in sleep disorders. Translational and Clinical Pharmacology, 30(4), 163–171. https://doi.org/10.12793/tcp.2022.30.e21
   PubMedGoogle Scholar
• Kundu, R., Banerjee, S., Baidya, S. K., Adhikari, N., & Jha, T. (2022). A quantitative structural analysis of AR-42 derivatives as HDAC1 inhibitors for the identification of promising structural contributors. SAR and QSAR in Environmental Research, 33(11), 861–883. https://doi.org/10.1080/1062936X.2022.2145353
   PubMedGoogle Scholar
• Lah, T. T., Novak, M., & Breznik, B. (2020). Brain malignancies: Glioblastoma and brain metastases. Seminars in Cancer Biology, 60, 262–273. https://doi.org/10.1016/j.semcancer.2019.10.010
   PubMed Web of Science ®Google Scholar
• Lanka, G., Begum, D., Banerjee, S., Adhikari, N., P, Y., & Ghosh, B. (2023). Pharmacophore-based virtual screening, 3D QSAR, Docking, ADMET, and MD simulation studies: An in silico perspective for the identification of new potential HDAC3 inhibitors. Computers in Biology and Medicine, 166, 107481. https://doi.org/10.1016/j.compbiomed.2023.107481
   PubMed Web of Science ®Google Scholar
• Laubach, J. P., Moreau, P., San-Miguel, J. F., & Richardson, P. G. (2015). Panobinostat for the treatment of multiple myeloma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21(21), 4767–4773. https://doi.org/10.1158/1078-0432.CCR-15-0530
   PubMed Web of Science ®Google Scholar
• Lo Cascio, C., McNamara, J. B., Melendez, E. L., Lewis, E. M., Dufault, M. E., Sanai, N., Plaisier, C. L., & Mehta, S. (n.d). Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells. JCI Insight, 6(17), e149232. https://doi.org/10.1172/jci.insight.149232
   PubMed Web of Science ®Google Scholar
• Louhichi, T., Saad, H., Dhiab, M. B., Ziadi, S., & Trimeche, M. (2018). Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype. BMC Cancer, 18(1), 49. https://doi.org/10.1186/s12885-017-3951-8
   PubMedGoogle Scholar
• Melesina, J., Simoben, C. V., Praetorius, L., Bülbül, E. F., Robaa, D., & Sippl, W. (2021). Strategies To Design Selective Histone Deacetylase Inhibitors. ChemMedChem, 16(9), 1336–1359. https://doi.org/10.1002/cmdc.202000934
   PubMed Web of Science ®Google Scholar
• Meng, W., Wang, B., Mao, W., Wang, J., Zhao, Y., Li, Q., Zhang, C., & Ma, J. (2019). Enhanced efficacy of histone deacetylase inhibitor panobinostat combined with dual PI3K/mTOR inhibitor BEZ235 against glioblastoma. Nagoya Journal of Medical Science, 81, 93–102. https://doi.org/10.18999/nagjms.81.1.93
   PubMed Web of Science ®Google Scholar
• Millard, C. J., Watson, P. J., Celardo, I., Gordiyenko, Y., Cowley, S. M., Robinson, C. V., Fairall, L., & Schwabe, J. W. R. (2013). Class I HDACs share a common mechanism of regulation by inositol phosphates. Molecular Cell, 51(1), 57–67. https://doi.org/10.1016/j.molcel.2013.05.020
   PubMed Web of Science ®Google Scholar
• Minniti, G., Niyazi, M., Alongi, F., Navarria, P., & Belka, C. (2021). Current status and recent advances in reirradiation of glioblastoma. Radiation Oncology, 16(1), 36. https://doi.org/10.1186/s13014-021-01767-9
   PubMed Web of Science ®Google Scholar
• Nalivaeva, N. N., Belyaev, N. D., Lewis, D. I., Pickles, A. R., Makova, N. Z., Bagrova, D. I., Dubrovskaya, N. M., Plesneva, S. A., Zhuravin, I. A., & Turner, A. J. (2012). Effect of sodium valproate administration on brain Neprilysin expression and memory in rats. Journal of Molecular Neuroscience: MN, 46(3), 569–577. https://doi.org/10.1007/s12031-011-9644-x
   PubMed Web of Science ®Google Scholar
• Nalivaeva, N. N., Belyaev, N. D., Zhuravin, I. A., & Turner, A. J. (2012). The Alzheimer’s amyloid-degrading peptidase, Neprilysin: Can we control it? International Journal of Alzheimer’s Disease, 2012, e383796. https://doi.org/10.1155/2012/383796
   PubMedGoogle Scholar
• Pavo, N., Arfsten, H., Cho, A., Goliasch, G., Bartko, P. E., Wurm, R., Freitag, C., Gisslinger, H., Kornek, G., Strunk, G., Raderer, M., Zielinski, C., & Hülsmann, M. (2019). The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naïve cancer patients. Scientific Reports, 9(1), 2554. https://doi.org/10.1038/s41598-019-38867-2
   PubMedGoogle Scholar
• Perrin, S. L., Samuel, M. S., Koszyca, B., Brown, M. P., Ebert, L. M., Oksdath, M., & Gomez, G. A. (2019). Glioblastoma heterogeneity and the tumour microenvironment: Implications for preclinical research and development of new treatments. Biochemical Society Transactions, 47(2), 625–638. https://doi.org/10.1042/BST20180444
   PubMedGoogle Scholar
• Prausmüller, S., Spinka, G., Arfsten, H., Stasek, S., Rettl, R., Bartko, P. E., Goliasch, G., Strunk, G., Riebandt, J., Mascherbauer, J., Bonderman, D., Hengstenberg, C., Hülsmann, M., & Pavo, N. (2021). Relevance of neutrophil Neprilysin in heart failure. Cells, 10(11), 2922. https://doi.org/10.3390/cells10112922
   PubMed Web of Science ®Google Scholar
• Pulya, S., Patel, T., Paul, M., Adhikari, N., Banerjee, S., Routholla, G., Biswas, S., Jha, T., & Ghosh, B. (2022). Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer. European Journal of Medicinal Chemistry, 238, 114470. https://doi.org/10.1016/j.ejmech.2022.114470
   PubMed Web of Science ®Google Scholar
• Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021). Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sciences, 277, 119504. https://doi.org/10.1016/j.lfs.2021.119504
   PubMed Web of Science ®Google Scholar
• Riddell, E., & Vader, J. M. (2017). Potential expanded indications for Neprilysin inhibitors. Current Heart Failure Reports, 14(2), 134–145. https://doi.org/10.1007/s11897-017-0327-y
   PubMedGoogle Scholar
• Sankhe, R., Pai, S. R. K., & Kishore, A. (2021a). Tumour suppression through modulation of neprilysin signaling: A comprehensive review. European Journal of Pharmacology, 891, 173727. https://doi.org/10.1016/j.ejphar.2020.173727
   PubMed Web of Science ®Google Scholar
• Sankhe, R., Rathi, E., Manandhar, S., Kumar, A., Pai, S. R. K., Kini, S. G., & Kishore, A. (2021b). Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study. Journal of Molecular Structure, 1224, 129073. https://doi.org/10.1016/j.molstruc.2020.129073
   PubMed Web of Science ®Google Scholar
• Sasmita, A. O., Wong, Y. P., & Ling, A. P. K. (2018). Biomarkers and therapeutic advances in glioblastoma multiforme. Asia-Pacific Journal of Clinical Oncology, 14(1), 40–51. https://doi.org/10.1111/ajco.12756
   PubMed Web of Science ®Google Scholar
• Silantyev, A. S., Falzone, L., Libra, M., Gurina, O. I., Kardashova, K., Sh, Nikolouzakis, T. K., Nosyrev, A. E., Sutton, C. W., Mitsias, P. D., & Tsatsakis, A. (2019). Current and future trends on diagnosis and prognosis of glioblastoma: from molecular biology to proteomics. Cells, 8(8), 863. https://doi.org/10.3390/cells8080863
   PubMed Web of Science ®Google Scholar
• Sixto-López, Y., Gómez-Vidal, J. A., de Pedro, N., Bello, M., Rosales-Hernández, M. C., & Correa-Basurto, J. (2020). Hydroxamic acid derivatives as HDAC1, HDAC6 and HDAC8 inhibitors with antiproliferative activity in cancer cell lines. Scientific Reports, 10(1), 10462. https://doi.org/10.1038/s41598-020-67112-4
   PubMed Web of Science ®Google Scholar
• Smollich, M., Götte, M., Yip, G. W., Yong, E.-S., Kersting, C., Fischgräbe, J., Radke, I., Kiesel, L., & Wülfing, P. (2007). On the role of endothelin-converting enzyme-1 (ECE-1) and neprilysin in human breast cancer. Breast Cancer Research and Treatment, 106(3), 361–369. https://doi.org/10.1007/s10549-007-9516-9
   PubMed Web of Science ®Google Scholar
• Terauchi, M., Kajiyama, H., Shibata, K., Ino, K., Mizutani, S., & Kikkawa, F. (2005). Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo. Oncology, 69(1), 52–62. https://doi.org/10.1159/000087476
   PubMed Web of Science ®Google Scholar
• Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014). Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 23(10), 1985–1996. https://doi.org/10.1158/1055-9965.EPI-14-0275
   PubMed Web of Science ®Google Scholar
• Torp, S. H., Solheim, O., & Skjulsvik, A. J. (2022). The WHO 2021 Classification of Central Nervous System tumours: A practical update on what neurosurgeons need to know—A minireview. Acta Neurochirurgica, 164(9), 2453–2464. https://doi.org/10.1007/s00701-022-05301-y
   PubMed Web of Science ®Google Scholar
• Uematsu, F., Takahashi, M., Yoshida, M., Igarashi, M., & Nakae, D. (2006). Methylation of neutral endopeptidase 24.11 promoter in rat hepatocellular carcinoma. Cancer Science, 97(7), 611–617. https://doi.org/10.1111/j.1349-7006.2006.00227.x
   PubMed Web of Science ®Google Scholar
• van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015). Overcoming the blood–brain tumor barrier for effective glioblastoma treatment. Drug Resistance Updates: Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 19, 1–12. https://doi.org/10.1016/j.drup.2015.02.002
   PubMed Web of Science ®Google Scholar
• Vichai, V., & Kirtikara, K. (2006). Sulforhodamine B colorimetric assay for cytotoxicity screening. Nature Protocols, 1(3), 1112–1116. https://doi.org/10.1038/nprot.2006.179
   PubMed Web of Science ®Google Scholar
• Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007). Histone deacetylase inhibitors: Molecular mechanisms of action. Oncogene, 26(37), 5541–5552. https://doi.org/10.1038/sj.onc.1210620
   PubMed Web of Science ®Google Scholar
• Yu, M. W., & Quail, D. F. (2021). Immunotherapy for glioblastoma: Current progress and challenges. Frontiers in Immunology, 12, 676301. https://doi.org/10.3389/fimmu.2021.676301
   PubMed Web of Science ®Google Scholar
• Zhang, L., Liu, Z., Dong, Y., & Kong, L. (2021). Epigenetic targeting of SLC30A3 by HDAC1 is related to the malignant phenotype of glioblastoma. IUBMB Life, 73(5), 784–799. https://doi.org/10.1002/iub.2463
   PubMed Web of Science ®Google Scholar